Psychedelic combo tested for safety in small human study
NCT ID NCT07079930
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study will give 10 healthy adults a single dose of psilocybin (the active ingredient in magic mushrooms) combined with D-serine, an amino acid. Researchers want to see if D-serine can tone down the psychedelic effects and improve safety. The goal is to find the right dose for future trials, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- psilocybin and D-serine
- What this could lead to
- If successful, this could help determine a safe dose for future studies exploring psilocybin's effects when combined with D-serine.
- What could go wrong
- This is a very early, small Phase 1 trial in only 10 healthy volunteers. It is designed to test safety, not effectiveness, and may not lead to any treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hadassah Medical Organization, Jerusalem, Israel
RECRUITINGJerusalem, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults